A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors. (26th November 2015)

• Record Type: Journal Article
• Authors: Bendell, Johanna C.; Jones, Suzanne F.; Hart, Lowell; Pant, Shubham; Moyhuddin, Adil; Lane, Cassie M.; Earwood, Chris; Murphy, Patrick; Patton, Jeffrey; Penley, William C.; Thompson, Dana; Infante, Jeffrey R.
• Is Part Of: Cancer investigation. Volume 33:Number 10(2015)
• Page Start: 477
• Page End: 482
• Publication Date: 2015-11-26
• Subjects: Hsp90 -- AUY922 -- Capecitabine; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.3109/07357907.2015.1069834
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract : Background : This phase I study determined the maximum tolerated dose (MTD) of AUY922 with capecitabine in advanced solid tumors. Methods : Capecitabine 1000mg/m 2 PO BID was administered with escalating doses of AUY922 IV; the MTD of AUY922 was combined with capecitabine 1250 mg/m 2 (DL6). Results : 23 patients were treated at 5 dose levels (22 mg/m 2 –70 mg/m 2 ). No DLTs were observed until DL6 (grade 3 diarrhea). Reversible vision darkening was seen in 26%. Four patients had partial response; 2 previously progressed on fluorouracil. Eight patients had stable disease (median 25.5 weeks). Conclusion : AUY922 plus capecitabine was well-tolerated up to 70mg/m 2 with encouraging preliminary efficacy.